Clinical Trial Update: Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating Izalontamab Brengitecan in combination with Adagrasib for non-small cell lung cancer; the study is currently not yet recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Adagrasib (adagrasib)
• Izalontamab Brengitecan

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Non-small Cell Lung Cancer | Phase 1 | Status: NOT_YET_RECRUITING